Challenges in the Use of DNA Repair Deficiency As a Biomarker in Breast Cancer.
Netherlands Cancer Institute, Amsterdam, the Netherlands.
Philip C
PC
Schouten
Netherlands Cancer Institute, Amsterdam, and University Medical Center Utrecht, Utrecht, the Netherlands s.linn@nki.nl.
Sabine C
SC
Linn
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D014408:Biomarkers, Tumor / Q000235:genetics*; D016190:Carboplatin / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use*; D005260:Female; D042822:Genomic Instability; D006801:Humans; D015412:Mastectomy, Segmental; D020360:Neoadjuvant Therapy / Q000379:methods*; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D019313:BRCA1 Protein; D024682:BRCA2 Protein; D014408:Biomarkers, Tumor; D016190:Carboplatin; D002945:Cisplatin